Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.61 |
| ▸ | MGAM | O43451 | 9/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 9/20 | 0.54 |
| ▸ | GAA | P10253 | 9/20 | 0.54 |
| ▸ | SI | P14410 | 9/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970279 | 0.84 | DGAT1 (0.66) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL28300681 | 0.82 | DGAT1 (0.63) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL1520814 | 0.81 | DGAT1 (0.72) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL29163194 | 0.81 | DGAT1 (0.61) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL443991 | 0.81 | GAA (0.64) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL27973795 | 0.79 | DGAT1 (0.70) | DGAT1MGAMAMY1AGAASI | |
| Hydrochloric Acid SCHEMBL2681010 | 0.79 | DGAT1 (0.70) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL13604213 | 0.77 | DGAT1 (0.56) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL4250719 | 0.76 | GAA (0.68) | DGAT1MGAMAMY1AGAASI | |
| SCHEMBL706083 | 0.76 | MGAM (0.68) | DGAT1MGAMAMY1AGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230261203-A1 | LITHIUM SECONDARY BATTERY | TERAWATT TECHNOLOGY K.K. (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2020197963-A1 | COATINGS FOR WATERPROOFING ELECTRONIC COMPONENTS | HENKEL AG & CO. KGAA (DE) | 2020-10-01 | — | — | WO | disclosed |
| EP-1973887-B1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | IMMUPHARMA FRANCE SA (FR) | 2012-09-19 | — | — | EP | disclosed |
| EP-1973887-B1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | IMMUPHARMA FRANCE SA (FR) | 2012-09-19 | — | — | EP | disclosed |
| US-20100291199-A1 | Compositions and Methods For The Treatment and Prevention of Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7777030-B2 | Compositions and methods for the treatment and prevention of disease | Centre National de la Recherge Scientifique (CNRS) (FR) | 2010-08-17 | — | — | US | disclosed |
| CN-101405276-A | Compositions and methods for the inhibition of phospholipase A2 | IMMUPHARMA FRANCE SA (FR) | 2009-04-08 | — | — | CN | disclosed |
| CN-101400352-A | Compositions and methods for the treatment and prevention of disease | IMMUPHARMA FRANCE SA (FR) | 2009-04-01 | — | — | CN | disclosed |
| CN-101395143-A | Aza heterocyclics for the treatment of malaria or aids | IMMUPHARMA FRANCE SA (FR) | 2009-03-25 | — | — | CN | disclosed |
| EP-1973887-A1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | Immupharma France SA (FR) | 2008-10-01 | — | — | EP | disclosed |
| EP-1965806-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DISEASE | IMMUPHARMA FRANCE SA (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-20080033167-A1 | Compositions and methods for synthesizing heterocyclic therapeutic compounds | UREKA SARL (FR) | 2008-02-07 | — | — | US | disclosed |
| US-20080031951-A1 | Compositions and methods for the inhibition of phospholipase A2 | IMMUPHARMA FRANCE SA (FR) | 2008-02-07 | — | — | US | disclosed |
| US-20070293469-A1 | Compositions and methods for the treatment and prevention of disease | UREKA SARL (FR) | 2007-12-20 | — | — | US | disclosed |
| WO-2007074169-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF PHOSPHOLIPASE A2 | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074169-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF PHOSPHOLIPASE A2 | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074170-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DISEASE | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074170-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF DISEASE | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074171-A1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074171-A1 | AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS | IMMUPHARMA FRANCE SA (FR) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291199-A1 | Compositions and Methods For The Treatment and Prevention of Disease | DNPEP, VIP, PEPD | DGAT1 3347/4885MGAM 2735/4885AMY1A 2521/4885 |
| US-20080031951-A1 | Compositions and methods for the inhibition of phospholipase A2 | PLA2G1B, PLA2G4A, PLA2G12A | DGAT1 535/4885MGAM 2238/4885AMY1A 1315/4885 |
| US-20070293469-A1 | Compositions and methods for the treatment and prevention of disease | DNPEP, VIP, PEPD | DGAT1 3347/4885MGAM 2735/4885AMY1A 2521/4885 |
| US-20080033167-A1 | Compositions and methods for synthesizing heterocyclic therapeutic compounds | DNPEP, VIP, NGLY1 | DGAT1 3177/4885MGAM 2584/4885AMY1A 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.